Vectura Group plc - Board Appointments
Vectura Group appoints
"I'm delighted to welcome
Commenting on her appointment,
"I am pleased to join the Board of Vectura at this exciting time and look forward to helping the Board build on the Company's position as a leading development services business, helping the business deliver significant benefits to a growing number of customers and their patients."
"As Vectura continues to build on its position as a leading inhalation specialist CDMO, I am excited to be working with the Board to help contribute to the Company's future growth."
There are no additional details to disclose under Listing Rule
- Ends -
For more information, please contact:
Vectura Group plc
| || |
+44 (0)7471 352 720
+44 (0)7767 160 565
Consilium Strategic Communications
+44 (0)20 3709 5700
| || |
Vectura is a provider of innovative inhaled drug delivery solutions that enable partners to bring their medicines to patients. With differentiated proprietary technology and pharmaceutical development expertise, Vectura is one of the few companies globally with the device, formulation and development capabilities to deliver a broad range of complex inhaled therapies.
Vectura has ten key inhaled and eleven non-inhaled products marketed by partners with global royalty streams, and a diverse partnered portfolio of drugs in clinical development. Our partners include Hikma, Novartis, Sandoz (a division of Novartis AG), Mundipharma, Kyorin, GSK, Bayer, Chiesi, Almirall, and Tianjin KingYork.
For further information, please visit Vectura's website at www.vectura.com.
Quick facts: Vectura Group PLC
Market Cap: -
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE